What is MS Phase 3 Study Laquinimod BRAVO?
CATEGORY:
NCT00605215 is a multinational, randomized, parallel-group study performed in subjects with RRMS to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and a reference arm of interferon β-1a. Other study IDs include: MS-LAQ-302, EUDRACT 2007-005450-23.
Save up to 80% off your prescriptions!
How do members experience MS Phase 3 Study Laquinimod BRAVO?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Participate in clinical trial | 1 | 0 |
Learn more about our community’s experience with MS Phase 3 Study Laquinimod BRAVO
What are people saying about MS Phase 3 Study Laquinimod BRAVO?
2
2
members have reported taking MS Phase 3 Study Laquinimod BRAVO
Join the conversation and connect with people who have taken MS Phase 3 Study Laquinimod BRAVO
Last updated: